Lantus SoloStar (Insulin Glargine 100 U/mL) by Sanofi is a pharmaceutical-grade long-acting insulin analogue delivered via a prefilled SoloStar injectable pen. Insulin glargine is a recombinant human insulin analogue with structural modifications that produce a distinct subcutaneous depot mechanism, conferring a peakless, 24-hour pharmacokinetic profile that is extensively documented in clinical and endocrinological literature as a reference standard in basal insulin therapy.
 
✔ Key Research Insights
Studied for its peakless 24-hour basal insulin coverage, with documented absence of pronounced pharmacodynamic peaks relative to intermediate-acting insulin preparations in research subjects
Investigated for its predictable and consistent glucose-lowering activity, associated with reduced glycaemic variability in clinical trial populations
Researched for its once-daily administration profile, with documented associations with improved treatment adherence and simplified basal insulin management protocols
Examined for its reduced risk of nocturnal hypoglycaemia relative to NPH insulin in comparative clinical trial literature involving Type 1 and Type 2 diabetic subject populations
Documented for its subcutaneous microprecipitate depot mechanism, providing a sustained and gradual insulin release over the 24-hour dosing interval in pharmacokinetic research
Manufactured by Sanofi to pharmaceutical-grade insulin innovation and safety standards
 
📦 Product Specifications
Manufacturer: Sanofi
Product: Lantus SoloStar
Molecule: Insulin Glargine
Concentration: 100 U/mL
Appearance: Clear, colorless injectable solution
Form: Prefilled SoloStar pen (subcutaneous injection)
Volume: Box of 5 prefilled pens
Clinical reference: dosage should be determined by a qualified healthcare professional. Once-daily subcutaneous administration at a consistent time each day is indicated per documented clinical protocols.
 
⚙ How It Works
Insulin glargine is a long-acting recombinant human insulin analogue in which asparagine at position A21 is replaced by glycine and two arginine residues are added to the C-terminus of the B-chain. These structural modifications shift the isoelectric point of the molecule, rendering it less soluble at physiological pH in research subjects. Following subcutaneous injection of the acidic formulation into physiological tissue pH, insulin glargine forms stable microprecipitates at the injection site, creating a subcutaneous depot from which small, consistent amounts of insulin are gradually released into systemic circulation. This depot mechanism is associated in clinical pharmacokinetic literature with a characteristically flat, peakless absorption profile extending across a 24-hour dosing interval, closely approximating the continuous low-level basal insulin secretion of the endogenous pancreas. The absence of pronounced pharmacodynamic peaks distinguishes insulin glargine from intermediate-acting preparations and is associated in comparative clinical trials with reduced nocturnal hypoglycaemia incidence. In basal-bolus therapy protocols, insulin glargine is referenced as the basal component, administered independently of meal timing to manage fasting and inter-meal glycaemic parameters across documented diabetic subject populations.
 
⭐ Product Overview
Manufactured by Sanofi, a globally recognized leader in insulin research, development, and pharmaceutical-grade production
Prefilled SoloStar pen delivery system supporting precise, consistent, and hygienic subcutaneous dosing per administration
Long-acting insulin analogue with one of the most extensively documented peakless pharmacokinetic profiles in basal insulin therapy literature
Indicated for basal insulin support in both Type 1 and Type 2 diabetes management, as referenced across international endocrinological and diabetes care guidelines
Widely recognized as a clinical reference standard in basal insulin therapy under the insulin glargine and Lantus designations worldwide